Tuberc Respir Dis > Volume 59(4); 2005 > Article
Tuberculosis and Respiratory Diseases 2005;59(4):423-426.
DOI: https://doi.org/10.4046/trd.2005.59.4.423    Published online October 1, 2005.
A Case of Imatinib-mesylate associated Hypersensitivity Pneumonitis.
Jae Wong Lee, Hye Jin Kim, Kyu Jin Kim, Kyeong Cheol Shin, Yeong Hoon Hong, Jin Hong Chung, Kwan Ho Lee
Department of Internal Medicine, College of Medicine, Yeungnam University, Korea. shin@med.yu.ac.kr
Abstract
Imatinib-mesylate (Gleevec, Glivec) is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib is also used to treat patients with c-kit (CD 117)-positive unresectable tumors, or metastatic malignant gastrointestinal stromal tumors, or both. Imatinib is a well- tolerated drug with few side effects. However, it has been associated with gastrointestinal irritation, fluid retention and edema, skin rashes, depigmentation, hepatotoxicity, hemorrhage, and hematological toxicity (anemia, neutropenia, and thrombocytopenia). In addition, imatinib has been associated with dyspnea and cough, which are mainly secondary to the pleural effusion and pulmonary edema, which represent local or general fluid retention. These events appear to be dose related and are more common encountered in the elderly. However, there has been no report of hypersensitivity pneumonitis associated with imatinib-mesylate in Korea. We report a case of 51-year old woman who developed hypersensitivity pneumonitis that might have been induced by imatinib-mesylate during the treatment of a gastrointestinal stromal tumor.
Key Words: Imatinib-mesylate, Hypersensitivity pneumonitis, Gastrointestinal stromal tumor


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next